Immunoadsorption in patients with neuromyelitis optica spectrum disorder.

Faissner, Simon; Nikolayczik, Johanna; Chan, Andrew; Gold, Ralf; Yoon, Min-Suk; Haghikia, Aiden (2016). Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic advances in neurological disorders, 9(4), pp. 281-286. Sage 10.1177/1756285616646332

Text 1756285616646332.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (473kB) | Request a copy

INTRODUCTION

Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder of the central nervous system, distinct from multiple sclerosis by affecting predominantly the optic nerve and the spinal cord, and mediated by antibodies directed against aquaporin 4 (AQP4-ab) as a possible pathomechanistic hallmark of NMOSD. Therapeutic options include immunosuppression with steroids or B-cell-depleting agents as baseline therapies, as well as plasma exchange (PLEX) and/or immunoadsorption (IA) during relapses. Until now, data concerning the efficacy of IA alone are scarce.

METHODS

Visual evoked potentials (VEPs), visual acuity and changes of symptoms at relapse leading to admission in NMOSD patients (n = 10) treated with IA in a single-centre setting were evaluated retrospectively.

RESULTS

All patients profited from the procedure and showed an amelioration of admission symptoms. Three patients improved in visual acuity, another three patients remained stable, whereas five patients showed an improvement in VEPs.

DISCUSSION

In this small cohort, IA constitutes a valid therapeutic option for patients with NMOSD as an equivalent to PLEX. Analysis in larger cohorts is warranted.

Interest & Impact

Downloads

2 since deposited on 03 May 2017
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item